# Nuoen Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nuoen-genomics

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.mirbay.com/
- Latest round: Series A (Nov 6, 2025)
- Investors on record: 1

## About

Nuoen Genomics, based in Chengdu, China, specializes in developing innovative genomic solutions for agricultural enhancement and sustainability through advanced biotechnological approaches.Founded in 2011 in Chengdu, China, Nuoen Genomics is dedicated to creating genomic solutions that support agricultural productivity. The company has undergone strategic shifts to focus on genomic technologies in agriculture. No known subsidiaries or mergers have influenced its current operations. The founder's background details are not publicly available.Chengdu Nuoen Biotechnology Co., Ltd. specializes in the development and production of innovative biological products aimed at enhancing agricultural productivity and sustainability. The company offers a range of solutions, including bio-based fertilizers and microbial agents designed to improve soil health, promote plant growth, and increase crop yields. These products are formulated to address specific agricultural challenges, such as nutrient deficiency and pest resistance, ultimately benefiting farmers and agricultural enterprises. The company serves a diverse client base that includes agricultural cooperatives, distribution partners, and individual farmers primarily within the Asian market, focusing on regions with high agricultural output and demand for sustainable farming practices.Chengdu Nuoen Biotechnology Co., Ltd. generates revenue through a structured model that includes direct sales to agricultural producers and partnerships with distributors. Business transactions typically involve bulk purchasing agreements with agricultural cooperatives and retailers, facilitating wider access to the company's products. The company’s flagship offerings are positioned as premium solutions in the market, catering to clients seeking effective and environmentally friendly agricultural products. Pricing models for these products are designed to reflect their quality and effectiveness, with tailored plans available for large-scale agricultural operations and strategic partnerships. This approach ensures a steady revenue stream while reinforcing the company's commitment to modern and sustainable agricultural practices.In November 2025, Nuoen Genomics raised an undisclosed amount of Series A funding from returning investor Agrand Capital. The company will use the funding to accelerate the research and development of its nucleic acid drug delivery and sequence modification platform technologies, enhance product pipeline innovation, and expand collaboration with partners in the biopharmaceutical industry. Upcoming products are expected to address new agricultural challenges, and the company aims to expand its reach into additional markets within Asia by 2026.

## Funding rounds

- Series A, Nov 6, 2025 — Agrand Capital

## Investors

- Agrand Capital (https://capitalatlas.ai/funds/agrand-capital) — Series A